Revenue
2022
2023
2024
2025
Mereo BioPharma Group plc (MREO)
Price$0.2500Cached quote
Net income
2022
2023
2024
2025
Free cash flow
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $500,000 | $0 | $10.0M | $0 | — | — | — | — | — | — |
| Research & development | $17.8M | $20.9M | $17.4M | $29.5M | — | — | — | — | — | — |
| Operating expenses | $700,000 | $700,000 | $700,000 | $900,000 | — | — | — | — | — | — |
| Operating income | −$40.1M | −$47.4M | −$28.4M | −$54.4M | — | — | — | — | — | — |
| Operating margin | −8,021.40% | — | −284.16% | — | — | — | — | — | — | — |
| EBITDA | −$39.5M | −$46.8M | −$27.9M | −$54.2M | — | — | — | — | — | — |
| EBITDA margin | −7,897.00% | — | −278.50% | — | — | — | — | — | — | — |
| Net income | −$41.9M | −$43.3M | −$29.5M | −$42.2M | — | — | — | — | — | — |
| Net profit margin | −8,375.60% | — | −294.66% | — | — | — | — | — | — | — |
| Basic EPSper basic share | -$0.05 | -$0.06 | -$0.04 | -$0.07 | — | — | — | — | — | — |
| Diluted EPSper diluted share | -$0.05 | -$0.06 | -$0.04 | -$0.07 | — | — | — | — | — | — |
Owners
Reported shareholders
Reported holdings Number of shares
View holders
| Holder | Shares held |
|---|---|
Rubric Capital Management LP | 15.31M |
683 Capital Management, LLC | 11.78M |
BANK OF AMERICA CORP /DE/ | 8.2M |
Defilade Capital Management, L.P. | 7.56M |
Newtyn Management, LLC | 3M |
Tejara Capital Ltd | 2.04M |
UBS Group AG | 1.45M |
TWO SIGMA INVESTMENTS, LP | 1.32M |
EcoR1 Capital, LLC | 1M |
JANE STREET GROUP, LLC | 774.94K |
Ishara Investments LP | 768.75K |
Wealthspire Advisors, LLC | 765K |
CITADEL ADVISORS LLC | 444.16K |
Rangeley Capital, LLC | 329.2K |
SUSQUEHANNA INTERNATIONAL GROUP, LLP | 213.27K |
MARSHALL WACE, LLP | 179.88K |
XTX Topco Ltd | 174.48K |
GROUP ONE TRADING LLC | 167.52K |
STATE STREET CORP | 134.77K |
NOMURA HOLDINGS INC | 104.36K |
Bars compare reported share counts. A matching total for this share class and reporting period is unavailable, so percentages are not shown.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Sep 13, 2024Form 4 | Scots-Knight DeniseChief Executive Officer | SellAmerican Depositary Shares representing Ordinary Shares | 60.0K | $4.22 | $253.4K | 808.9K |
| Sep 13, 2024Form 4 | Lewicki John A.Chief Scientific Officer | SellAmerican Depositary Shares representing Ordinary Shares | 10.9K | $4.22 | $46.2K | 78.6K |
| Sep 13, 2024Form 4 | Sermon CharlesGeneral Counsel | SellAmerican Depositary Shares representing Ordinary Shares | 20.9K | $4.22 | $88.4K | 219.1K |
| Sep 13, 2024Form 4 | Fox Christine AnnChief Financial Officer | SellAmerican Depositary Shares representing Ordinary Shares | 19.2K | $4.22 | $80.8K | 89.3K |
| Sep 13, 2024Form 4 | Hughes-Wilson AlexandraSee Remarks | SellAmerican Depositary Shares representing Ordinary Shares | 84.0K | $4.22 | $354.5K | 50.5K |